US EditionCStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR
- CStone Pharmaceuticals shared findings from studies on CS2009, a novel antibody targeting PD-1, VEGF, and CTLA-4, during the poster session 39, Board 14, at the 2025 AACR Annual Meeting on April 30, 2025.
- This presentation followed ongoing global phase I trials of CS2009 initiated in Australia in March 2025, with planned expansions to China and the US to explore its clinical potential.
- CS2009 targets three validated immunotherapy checkpoints, showing synergistic anti-tumor effects, enhanced affinity upon dual target engagement, and increased activity via VEGFA crosslinking in tumor microenvironments.
- Notably, CS2009 demonstrated approximately 150-fold and 300-fold increases in checkpoint inhibitory and immune checkpoint activities respectively, while exhibiting favorable pharmacokinetics and tolerability with a no observed adverse effect level of 100 mg/kg.
- These findings suggest CS2009 may become a next-generation backbone immuno-oncology therapy with broad applications across solid tumors, potentially outperforming existing PD-1 and bispecific antibodies.
Insights by Ground AI
Does this summary seem wrong?
34 Articles
34 Articles
All
Left
3
Center
9
Right
1
InsideNoVA.com+32 Reposted by 32 other sources
CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR
SUZHOU, China, May 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a key asset in CStone Pipeline…
Coverage Details
Total News Sources34
Leaning Left3Leaning Right1Center9Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 23%
C 69%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
